Regenxbio Inc
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular … Read more
Regenxbio Inc (RGNX) - Total Assets
Latest total assets as of September 2025: $525.20 Million USD
Based on the latest financial reports, Regenxbio Inc (RGNX) holds total assets worth $525.20 Million USD as of September 2025.
Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Regenxbio Inc - Total Assets Trend (2013–2024)
This chart illustrates how Regenxbio Inc’s total assets have evolved over time, based on quarterly financial data. Explore and compare other companies by total assets.
Regenxbio Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Regenxbio Inc's total assets of $525.20 Million consist of 59.7% current assets and 40.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 12.3% |
| Accounts Receivable | $21.57 Million | 4.6% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2013–2024)
This chart illustrates how Regenxbio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Regenxbio Inc's current assets represent 59.7% of total assets in 2024, a decrease from 87.9% in 2013.
- Cash Position: Cash and equivalents constituted 12.3% of total assets in 2024, down from 44.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 4.6% of total assets.
Regenxbio Inc Competitors by Total Assets
Key competitors of Regenxbio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
MedPacto Inc
KQ:235980
|
Korea | ₩51.58 Billion |
|
2H0
F:2H0
|
Germany | €15.27 Million |
|
Shenzhen CAU Technology Co Ltd
SHE:000004
|
China | CN¥260.55 Million |
|
Pacific Shuanglin Bio pharmacy Co Ltd
SHE:000403
|
China | CN¥9.58 Billion |
|
Nanhua Bio Medicine Co Ltd
SHE:000504
|
China | CN¥841.96 Million |
|
Jiangsu Sihuan Bioengineering Co Ltd
SHE:000518
|
China | CN¥509.14 Million |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
|
Hualan Biological EngineeringInc
SHE:002007
|
China | CN¥16.27 Billion |
Regenxbio Inc - Asset Efficiency Metrics
Asset efficiency metrics measure how effectively a company uses its assets to generate revenue and profits. These indicators help investors evaluate management's ability to deploy capital efficiently.
Asset Turnover Ratio
Measures how efficiently a company uses its assets to generate sales
Lower asset utilization - Regenxbio Inc generates 0.18x its asset value in annual revenue.
Return on Assets (ROA)
Measures how efficiently a company uses its assets to generate profits
Negative ROA - Regenxbio Inc is currently not profitable relative to its asset base.
Regenxbio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.66 | 3.05 | 6.52 |
| Quick Ratio | 2.66 | 3.17 | 6.39 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $207.40 Million | $ 210.67 Million | $ 449.75 Million |
Regenxbio Inc - Advanced Valuation Insights
This section examines the relationship between Regenxbio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.50 |
| Latest Market Cap to Assets Ratio | 0.77 |
| Asset Growth Rate (YoY) | -18.8% |
| Total Assets | $465.99 Million |
| Market Capitalization | $360.15 Million USD |
Valuation Analysis
Below Book Valuation: The market values Regenxbio Inc's assets below their book value (0.77 x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Regenxbio Inc's assets decreased by 18.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Regenxbio Inc (2013–2024)
The table below shows the annual total assets of Regenxbio Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $465.99 Million | -18.81% |
| 2023-12-31 | $573.97 Million | -31.12% |
| 2022-12-31 | $833.27 Million | -25.19% |
| 2021-12-31 | $1.11 Billion | +57.29% |
| 2020-12-31 | $708.16 Million | +42.23% |
| 2019-12-31 | $497.91 Million | -8.44% |
| 2018-12-31 | $543.81 Million | +173.72% |
| 2017-12-31 | $198.68 Million | +15.02% |
| 2016-12-31 | $172.73 Million | -21.97% |
| 2015-12-31 | $221.38 Million | +6241.45% |
| 2014-12-31 | $3.49 Million | +39.08% |
| 2013-12-31 | $2.51 Million | -- |